A Competitive Inhibitor That Reduces Recruitment of Androgen Receptor to Androgen-responsive Genes by Cherian, Milu T. et al.
A Competitive Inhibitor That Reduces Recruitment of
Androgen Receptor to Androgen-responsive Genes*□S
Received for publication, January 27, 2012, and in revised form, April 26, 2012 Published, JBC Papers in Press, May 15, 2012, DOI 10.1074/jbc.M112.344671
Milu T. Cherian‡, Elizabeth M. Wilson§, and David J. Shapiro¶1
From the Departments of ¶Biochemistry and ‡Molecular and Integrative Physiology, University of Illinois, Urbana, Illinois 61801-3602 and
§Laboratories for Reproductive Biology, Departments of Pediatrics and Biochemistry and Biophysics and Lineberger Comprehensive
Cancer Center, University of North Carolina, Chapel Hill, North Carolina 27599-7500
Background: Androgen receptor (AR) is a major therapeutic target for inhibiting proliferation of prostate cancer cells.
Results: A newly identified AR inhibitor, CPIC, works by reducing AR binding to regulated genes.
Conclusion: CPIC has a different mode of action from classical AR antagonists such as bicalutamide.
Significance: CPIC has therapeutic potential in the treatment of prostate cancer and is a new tool for studying AR.
The androgen receptor (AR) has a critical role in the growth
and progression of androgen-dependent and castration-resis-
tant prostate cancers. To identify novel inhibitors of AR trans-
activation that block growth of prostate cancer cells, a lucifer-
ase-based high-throughput screen of160,000 small molecules
was performed in cells stably expressing AR and a prostate-spe-
cific antigen (PSA)-luciferase reporter. CPIC (1-(3-(2-chloro-
phenoxy) propyl)-1H-indole-3-carbonitrile) was identified as a
small molecule that blocks AR transactivation to a greater
extent than other steroid receptors. CPIC inhibited AR-medi-
ated proliferation of androgen-sensitive prostate cancer cell
lines, with minimal toxicity in AR-negative cell lines. CPIC
treatment also reduced the anchorage-independent growth of
LAPC-4 prostate cancer cells. CPIC functioned as a pure antag-
onist by inhibiting the expression of AR-regulated genes in
LAPC-4 cells that expresswild-typeAR and exhibitedweak ago-
nist activity in LNCaP cells that express the mutant AR-T877A.
CPIC treatment did not reduce AR levels or alter its nuclear
localization. We used chromatin immunoprecipitation to iden-
tify the site of action of CPIC. CPIC inhibited recruitment of
androgen-bound AR to the PSA promoter and enhancer sites to
a greater extent than bicalutamide. CPIC is a new therapeutic
inhibitor that targets AR-mediated gene activation with poten-
tial to arrest the growth of prostate cancer.
Androgens such as testosterone and dihydrotestosterone
(DHT),2 mediate their biological effects through the nuclear
androgen receptor (AR). Binding of high affinity androgens to
the ligand binding domain of AR induces the interdomain ami-
no- and carboxyl-terminal (N/C) interaction (1–3). Activated
AR translocates and accumulates in the nucleus, where it binds
to specific androgen response elements (AREs) in the promoter
and enhancer regions of androgen-regulated genes and initiates
transcription by recruiting multiple coregulators and the basal
transcriptionmachinery in a sequential and cyclic fashion (4, 5).
Inhibitors of AR-mediated transcription include selective AR
modulators such as the prostate cancer therapeutic, bicalut-
amide (Casodex), and the experimental drug MDV3100.
Bicalutamide (Bic) and MDV3100 inhibit AR transcriptional
activity by competing with androgens for binding to the ligand
binding domain of AR (6, 7). Bicalutamide can exhibit some
agonist activity in cells containing mutant AR or expressing
high AR levels (8, 9).
Androgens play a central role in the growth and development
of the normal prostate gland and in the proliferation and pro-
gression of prostate cancers (10, 11). Patients with low grade
tumors benefit from primary therapies for prostate cancer,
including radical prostatectomy and androgen deprivation or
anti-androgen therapy.However, these treatment strategies are
much less effective for long term treatment of high grade
tumors (Gleason score 7) with elevated recurrence rates after
primary therapy. In castration-resistant (or castration-recur-
rent) prostate cancer (CRPC), there may be higher levels of AR
(12), increased expression of AR-regulated genes (13–15), and
AR coregulators such as MAGE-A11 and SRC/p160 coactiva-
tors (16–19), suggesting that these cancers remain dependent
on AR. Several types of evidence support the continuing role of
AR in CRPC. Many of the genes induced by androgens in
androgen-dependent prostate cancer xenografts become ele-
vated in CRPC (20). Recent studies show that many advanced
prostate cancers fuel their growth by synthesizing their own
androgens (21). AR continues to be a focus for new drug devel-
opment, and it remains important to identify antagonists that
block AR transcriptional activity (22). The importance of new
approaches to targeting androgens and AR in CRPC is illus-
trated by Abiraterone acetate/Zytiga, an androgen synthesis
inhibitor that prolongs survival in patients with advanced pros-
tate cancer (23).
* This work was supported, in whole or in part, by National Institutes of Health
Grants DK-071909 (to D. J. S.), HD16910 (to E. M. W.), and P01-CA77739
(NCI; to E. M. W.). This work was also supported by Department of Defense
Prostate Cancer Research Program Grant W81XWH-09-1-0309 (to D. J. S.).
□S This article contains supplemental Figs. S1–S8 and Methods 1 and 2.
1 To whom correspondence should be addressed. Tel.: 217-333-1788; Fax:
217-244-5858; E-mail: djshapir@life.illinois.edu.
2 The abbreviations used are: DHT, dihydrotestosterone; AR, androgen recep-
tor; ARE, androgen response element; Bic, bicalutamide; CD-FBS, charcoal-
dextran stripped FBS; CPIC, 1-(3-(2-chlorophenoxy)propyl)-1H-indole-3-
carbonitrile; CRPC, castration-resistant prostate cancer; ER, estrogen
receptor; GR, glucocorticoid receptor; PSA, prostate-specific antigen;
R1881, synthetic androgen methyltrienolone; R1881-AR, AR activated by
the binding of R1881; MEM, minimum essential medium; Luc, luciferase;
N/C, amino- and carboxyl-terminal interaction.
THE JOURNAL OF BIOLOGICAL CHEMISTRY VOL. 287, NO. 28, pp. 23368 –23380, July 6, 2012
© 2012 by The American Society for Biochemistry and Molecular Biology, Inc. Published in the U.S.A.
23368 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 287 • NUMBER 28 • JULY 6, 2012
To search for new AR antagonists, we developed and imple-
mented a cell-based high-throughput screen of160,000 small
molecules using HeLa cells that stably express AR and an
androgen-inducible PSA-luciferase reporter. The relatively
high levels of AR in these cells and the high concentration of
androgen we used in the screens rendered bicalutamide largely
ineffective as an AR antagonist. Here we describe 1-(3-(2-chlo-
rophenoxy)propyl)-1H-indole-3-carbonitrile (CPIC), a lead
compound that emerged from our screen. CPIC is a potent and
selective AR antagonist that inhibits expression of endogenous
AR-regulated genes and the androgen-dependent growth of
prostate cancer cells. Chromatin immunoprecipitation (ChIP)
assays using the synthetic androgen methyltrienolone (R1881)
showed that CPIC decreased AR occupancy at AREs of two
prominent AR-regulated genes, PSA and TMPRSS2, without
affecting AR protein levels or AR nuclear translocation. In
LNCaP cells that express a mutant AR-T877A and in LAPC-4
cells withwild-typeAR,CPIC inhibited binding of R1881-AR to
the PSA promoter and enhancer. The ability of CPIC to reduce
recruitment of AR to multiple regulatory regions of androgen-
responsive genes to a greater extent than bicalutamide suggests
a new mode of action.
EXPERIMENTAL PROCEDURES
Chemical Libraries—The libraries screened were the Chem-
Bridge MicroFormat small molecule library obtained from
ChemBridgeTM containing 150,000 small molecules, the
Marvel library developed at the University of Illinois by K. Putt
andHergenrother (24) containing9,700 small molecules, and
the NCI Diversity Set from NIH with 1,990 small molecules.
Plasmids—Expression vectors used have been previously
described (25). pCMV-AR-(507–919) codes for the human AR
DNA and ligand binding domains, and pCMV-AR-(1–503)
codes for the ARN-terminal domain. PSA-Enh-Luc containing
the PSA upstream enhancer region was generously provided by
Michael Carey (University of California, Los Angeles).
Cell Culture—AR-positive cell lines included LNCaP and
LAPC-4 human prostate cancer cells maintained in phenol-red
free RPMI 1640 with 10% fetal bovine serum (FBS, Atlanta Bio-
logical, GA). LAPC-4 growth medium was routinely supple-
mented with 1 nM synthetic androgen R1881. Cells were trans-
ferred to RPMI 1640 containing 5% charcoal-dextran-stripped
FBS (CD-FBS) at least 3 days before plating for an experiment.
CWR-R1 cells were grown in modified iMEM (GIBCO#10488-
001) containing 2.5 g/liter glucose, 1.2 g/liter niacinamide, 0.5
ml of insulin-transferrin-selenium (ITS, RocheApplied Science
#11074547001), 10 ng/ml epidermal growth factor (EGF), and
2% FBS. The cells were transferred to medium containing 2%
CD-FBS without EGF 3–4 days before the experiment.
HeLa-AR1C-PSA-ARE-Luc-A6 (HeLaA6) cells selectedwith
hygromycin and Geneticin (G418) stably express human AR
and a PSA-luciferase reporter gene containing the 5.8-kb PSA
upstream enhancer and promoter region linked to the lucifer-
ase gene (26). HeLa-AR3A-PSA-ARE4-Luc-13 (HeLa13) cells
selected with hygromycin and G418 stably express human AR
and a PSA-luciferase reporter gene containing a 4 multi-
merized PSA upstream enhancer ARE1 linked to the E4 TATA
box and luciferase gene. Both HeLa-AR cell lines were main-
tained in MEM supplemented with 10% FBS. HeLaA6 cells
weremaintained under selection with 0.1mg/ml hygromycin B
and 0.5 mg/ml Geneticin. HeLa13 cells were maintained under
selection with 0.05 mg/ml hygromycin B and 0.5 mg/ml G418.
Cells were transferred to medium containing 5% CD-FBS 3–4
days before the experiment. AR-negative cell lines included
PC-3 human prostate cancer cells maintained in RPMI 1640
with 10% FBS and DU145 human prostate cancer cells and
MDA-MB-231 human breast cancer cells grown in MEM with
10% FBS.
Other cell lines included estrogen receptor  (ER)-contain-
ing T47D-KBluc breast cancer cells expressing an estrogen-
responsive element (ERE)3-luciferase reporter gene (27), main-
tained in RPMI 1640 containing 10% FBS. Three days before
induction with 17-estradiol, cells were transferred tomedium
containing 5% CD-FBS. T47D/(A1–2) cells stably express the
human glucocorticoid receptor (GR) and contain a mouse
mammary tumor virus-luciferase reporter (28) and were main-
tained in MEM, 5% FBS, and 0.2 mg/ml G418. Mouse mam-
mary tumor virus-Luc reporter is inducible by AR, progester-
one receptor (PR), and GR depending on the activating ligand
used. Before the experiment, cells were transferred to the above
medium containing 5% CD-FBS.
The RPMI basemediumwas supplemented with 2mM L-glu-
tamine, 1.5 g/liter sodium bicarbonate, 4.5 g/liter glucose, 10
mM Hepes, pH 7.5, and 1 mM sodium pyruvate. MEMwas sup-
plemented with 10 mM HEPES, pH 7.4, and 2 mM L-glutamine.
All cells weremaintained at 37 °C in 5%CO2 in growthmedium
containing 1% penicillin and streptomycin and 2–10% FBS
(Atlanta Biological, Atlanta, GA) without phenol red.
Soft-agar Colony Formation Assay—To assay anchorage-in-
dependent cell growth in soft agar, 1 and 0.7% Select Agar
(Invitrogen) was prepared in water and warmed at 40 °C before
use. 1.5 ml of 0.5% bottom agar diluted in 2 RPMI 1640
mediumwas added to eachwell of a 6-well cell culture plate and
allowed to solidify at room temperature. Top agarwas prepared
by dilution in warm medium. LAPC-4 cells were resuspended
in 1.5 ml of 0.35% top agar at 5000 cells/well and plated in 3
wells for each condition. The plates were kept at room temper-
ature for 30 min until the top agar solidified, then 0.5 ml of
mediumcontaining the respective treatmentswas added on top
of the agar. Culture medium containing the various treatments
was changed every 3–4days. Colonieswere visible after 2weeks
in the hormone-treated wells and counted at day 28 using a
dissecting microscope. Photographs of colonies were taken
using aZeissAxioImager2 imaging systemat 5magnification.
Reporter Gene Assays—At least 3 days before each experi-
ment cells were transferred to medium containing CD-FBS as
described above. HeLaA6 and HeLa13 cells (50,000 cells/well)
and T47DA/1-2 or T47D-KBluc cells (200,000 cells/well) were
plated in 1 ml of medium in 24-well plates. After 24 h the indi-
cated concentrations of 17-estradiol, DHT, or dexamethasone
were added along with each inhibitor or DMSO (vehicle). After
24 h of treatment, cells were lysed in 100 l of Passive Lysis
Buffer (Promega, Madison, WI), and luciferase activity was
determined using BrightGlo firefly luciferase reagent (Pro-
mega). Unless otherwisementioned, total DMSO (vehicle) con-
centration in all assays was maintained at or below 0.1%.
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CellGrowth andViabilityAssays—Toassay cell growth, 2000
cells/well were plated in 96-well plates. LNCaP and LAPC-4
cells weremaintained inCD-treated serum for at least 2–4 days
before each experiment. All AR negative cell lines, MDA-MB-
231, DU145, and PC-3, were plated in growth medium 24 h
before treatment. Treatmentmedium containing vehicle or the
indicated concentrations of R1881 with or without inhibitor
compounds was added to the cells and incubated for the indi-
cated number of days. Cell viability was determined using Pro-
mega CellTiter 96 Aqueous One Solution Cell Proliferation
Assay (MTS).
Transient Transfection—LAPC-4 cells were plated (200,000
cells/well in 1 ml) in 24-well plates in 5% CD-FBS 3 days before
transfection. On the day of transfection, the medium was
changed to 0.2 ml of Opti-MEM. DNA and Lipofectamine2000
(Invitrogen)were diluted inOpti-MEMand incubated together
for 20 min before adding to the well. A total of 500 ng of DNA
(400 ng of PSA-Luc and 100 ng Renilla-Luc) was transfected
into cells in each well at a DNA:Lipofectamine2000 ratio of 1:3.
24 h after transfection, 1 nM R1881 and the indicated concen-
trations of each inhibitor in DMSOwere added to the cells and
incubated for 48 h. Cells were lysed in 100 l of passive lysis
buffer (Promega), and luciferase activity was determined using
Dual-Luciferase Reporter Assay (Promega #E1910). Transfec-
tions in HeLa cells were performed as described (29).
Radioligand Binding Assay—Competitive radioligand bind-
ing assays were performed by expressing pCMV-AR in mon-
key kidney COS cells and incubating cell cultures for 2 h at
37 °C with [3H]R1881 (17-methyl-[3H] methyltrienolone,
82 Ci/mmol) in the absence and presence of competitor
ligands (30, 31).
Endogenous Gene Expression—LNCaP and LAPC-4 cells
were seeded into 6-well plates and grown for 3–4 days in
medium containing 5% CD-FBS. Cells were then treated with
ethanol or R1881 alongwith the indicated concentrations of the
inhibitor for 24 h. RNA was extracted and purified using the
Qiagen RNeasy kit. cDNAwas prepared from 1g of RNAwith
M-MuLV reverse transcriptase from New England Biolabs.
Diluted cDNAwas used to perform quantitative RT-PCR using
SYBR Green (ABI Thermocycler) with actin as the internal
standard. Primers for quantitative RT-PCR were: -actin for-
ward primer (5-TGT CAC CAA CTG GGA CGA CA) and
reverse primer 5-GGG GTG TTG AAG GTC TCA AA); PSA
(kallikrein 3) forward primer (5-GGT GAC CAA GTT CAT
GCTGTG) and reverse primer (5-GTG TCC TTGATC CAC
TTCCG); TMPRSS2 forward primer (5-TAGTGAAACCAG
TGTGTC TGC) and reverse primer (5-AGCGTT CAGCAC
TTC TGA GGT CTT) (6).
Western Blot—Cells were plated at 300,000 cells/well in
6-well plates in medium containing 5% CD-FBS. The medium
was changed on day 2, and on day 4 the cells received fresh
medium containing the indicated treatments. Whole cell
extracts were prepared after 24 h of treatment using 1 radio-
immune precipitation assay buffer (Millipore) containing com-
plete mini protease inhibitor mixture (Roche Applied Science).
30 g of protein per lane was analyzed on 10% SDS-PAGE gels
and transferred to nitrocellulose membranes (GE Healthcare).
AR protein was detected using AR antibody AR (441) (sc-7305,
Santa Cruz, CA), internal control -tubulin was detected using
monoclonal antibody T1699 (Sigma), and -actin was detected
using antibody A1978 (Sigma).
ChIP—LNCaPor LAPC-4 cellswere grown in 5%CD-FBS for
4 days and pretreated with 10 M CPIC, Bic, or DMSO as con-
trol for 1 h before treatment with 1 nM R1881 or vehicle (etha-
nol) for 4 h. Proteins were cross-linked with 1% formaldehyde
for 10 min. Cell extracts were digested for 10 min with 50 units
of micrococcal nuclease (New England Biolabs) at 37 °C and
further sonicated to yield shearedDNA fragmentswith an aver-
age length of 200–1000 base pairs. The sonicated samples were
pelleted by centrifugation, and the supernatant was diluted
5-fold with ChIP dilution buffer (0.01% SDS, 1.1% Triton
X-100, 1.2mMEDTA, 16.7mMTris-HCl, pH 8.1, 167mMNaCl,
and protease inhibitor mixture). 50 l of diluted supernatant
was reserved as input (10%) for each treatment. The samples
were preclearedwith 50l of protein A-Sepharose™ 4 Fast Flow
(GE Healthcare) in ChIP dilution buffer (1:1) preblocked with
200 g/ml sheared herring sperm DNA and 500 g/ml BSA.
The samples were then divided, and the remaining proteins
were incubated with either 2 g of anti-AR (C19), 2 g of anti-
RNA polymerase II (clone CTD4H8, Millipore), or control
mouse IgG overnight at 4 °C. The antibody-protein-DNA com-
plex was precipitated by incubating with 50 l of Protein
A-SepharoseTM beads for 2 h at 4 °C. The protein-DNA com-
plex was eluted from the beads with elution buffer (1% SDS, 0.1
M NaHCO3). Cross-links were reversed, and DNA was eluted
from the protein-DNA complexes by adding 200 mMNaCl and
incubating overnight at 65 °C. Protein was digested using Pro-
teinase K and incubating at 45 °C for 2 h. DNA was recovered
and purified. Quantitative RT-PCR was performed to deter-
mine the change in AR and RNA polymerase II occupancy at
various sites of AR binding. The double negative controls were
nonspecific antibody (normal mouse IgG) and primers coding
for intergenic regions that do not interact with AR. Thermal
cycling conditions were 95 °C for 10 min followed by 50 cycles
of 25 s at 95 °C, 30 s at 60 °C, and 30 s at 72 °C. Primers used
were: PSA enhancer ARE forward primer (5-ACC TGC TCA
GCC TTT GTC TCT GAT) and reverse primer (5-AGA TCC
AGGCTTGCTTACTGTCCT); PSA promoter ARE forward
primer (5-CCT AGA TGA AGT CTC CAT GAG CTA CA)
and reverse primer (5-GGG AGG GAG AGC TAG CAC
TTG); middle region forward primer (5-CTGTGCTTGGAG
TTT ACC TGA) and reverse primer 5-GCA GAG GTT GCA
GTG AGC C) (32–34).
Statistical Analysis—Results are expressed as the mean 
S.E. of at least three independent experiments. Significance was
established when p  0.05. Student’s t test was used for com-
parison of the means between two groups.
RESULTS
Establishment of StableHeLaCell Lines andCell-basedHigh-
throughput Screening—For this work HeLaA6 (26) andHeLa13
cells were established to stably express PSA-ARE-Luc reporter
genes and AR at levels similar to or greater than LNCaP and
LAPC-4 cells. HeLaA6 cells express considerably more AR
protein than prostate cancer cell lines like LNCaP or LAPC-4
(35) (Fig. 1A). The higher level of AR results in 10–40 M
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bicalutamide acting as an agonist in HeLaA6 cells (supple-
mental Fig. S1A), and in this regard they resemble CRPC. To
more nearly mimic the environment of early-stage prostate
cancer, we established the HeLa13 cell line that stably
expresses AR protein at levels similar to LNCaP and LAPC-4
cells (Fig. 1A). There is a 20-fold difference in the dose-
response curves between the two cell lines. The half-maxi-
mal effective DHT concentration (EC50) was 50 pM in the
HeLaA6 cells compared with 1 nM in the HeLa13 cells
(Fig. 1B).
To identify new small molecule inhibitors of AR action, we
performed a luciferase-reporter based high-throughput screen
using HeLaA6 cells and 160,000 small molecules in several
libraries at the University of Illinois High-throughput Screen-
ing Facility. Feasibility for the cell-based high-throughput
screen was established using a combination of manual and
robotic steps. In preliminary experimentswe tested two screen-
ing methods. The more classical method of first plating the
cells, waiting 24 h, and adding the small-molecule test com-
pounds and an alternative approach of adding the inhibitor and
cells simultaneously to the wells (supplemental Methods 1 and
2). Although we were concerned that many small molecules
might interfere with cell attachment, we found that the two
methods yielded similar outcomes (supplemental Fig. S2).
Because Method 2 was easier to automate, it was used in the
large-scale screen.
Identification of CPIC as Lead Compound—Tominimize the
detection ofmoderate affinity competitor ligands,HeLaA6 cells
were assayed in the presence of 5 nM DHT to fully saturate AR
(see Fig. 1B). The lead inhibitor to emerge from our studies,
CPIC (Fig. 2A), was subsequently shown to be a competitive
inhibitor of androgen binding to AR.We evaluated the potency
of CPIC in cells expressing high (HeLaA6) and moderate
(HeLa13) levels of AR. The potency of CPIC in HeLaA6 and
HeLa13 cells was compared with bicalutamide, a competitive
AR antagonist that inhibits androgen binding to AR. CPIC elic-
ited a concentration-dependent inhibition ofAR-induced lucif-
erase activity in the HeLaA6 cells with an IC50 of 5 M and was
much more effective in HeLa13 cells with an IC50 of 0.09 M
(Fig. 2B). In contrast to bicalutamide, which had substantial
agonist activity in HeLaA6 cells in the absence of DHT, CPIC
lacked agonist activity in these cells (supplemental Fig. S1) and
thus functioned as a pure antagonist.
To evaluate the potency of CPIC in prostate cancer cells con-
taining wild-type AR, LAPC-4 human prostate cancer cells
FIGURE 1. Comparison of AR level and activity in HeLaA6 and HeLa13
cells. A, a Western blot shows AR levels in HeLaA6 and HeLa13 cells. After at
least 3 days in medium containing 5% CD-FBS, ethanol () or 10 nM DHT ()
was added. After 24 h, the cells were harvested, protein was extracted, and
equal amounts of protein were fractionated on 10% polyacrylamide gels and
analyzed by Western blotting. Tubulin served as a loading control. B, shown
are the DHT dose-response curves for HeLaA6 and HeLa13 cells. HeLaA6 or
HeLa13 cells were plated 1 day before treatment with the indicated concen-
trations of DHT or ethanol (vehicle) control. After 24 h of incubation, lysates
were prepared, and PSA luciferase activity was measured in extracts from
three wells of cells (mean  S.E.). Activity in the presence of saturating DHT
was set to 100%.
FIGURE 2. CPIC inhibits androgen induction of PSA-luciferase activity. A, shown is the structure of CPIC. B, dose-response studies of CPIC inhibition of
DHT-AR induced PSA-luciferase in HeLaA6 and HeLa13 cells. Cells were seeded in 24-well plates and treated with medium  10 nM DHT containing DMSO (Veh),
the indicated concentrations of CPIC, or 10 M bicalutamide (Bic) for 24 h and assayed for PSA luciferase activity. Activity of the reporter in the presence of 10
nM DHT and DMSO vehicle was set to 100%. Data represent the mean of three experiments S.E. C, LAPC-4 cells transiently transfected with 400 ng of
PSA-Enh-luciferase plasmid and 100 ng of CMV-Renilla luciferase were treated with the indicated concentrations of CPIC or DMSO in the presence of 2 nM R1881
for 48 h. Cell lysates were assayed for firefly luciferase and normalized with Renilla-luciferase activity. Bars represent the mean of three experiments  S.E.
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were transfected with PSA-luciferase reporter. CPIC effectively
inhibited luciferase activity induced by R1881-AR with an IC50
of 1–5 M (Fig. 2C).
CPIC Competes with Androgen for Binding to AR and Dis-
rupts ARN/C Interaction—The ability of CPIC to competewith
R1881 binding to AR was evaluated in cell-based assays. In
competitive radiometric binding assays performed using 5 nM
[3H]R1881, CPIC competed for binding toAR (Fig. 3A). If CPIC
is a competitive inhibitor of AR, increasing the hormone
concentration should reduce the ability of CPIC to bind AR
and block its action. To test this, we varied the DHT concen-
tration by 100-fold and tested the ability of CPIC to inhibit
PSA-Luc in HeLaA6 cells. Increasing the concentration of
DHT from 0.1 to 10 nM increased the IC50 for inhibiting
DHT-AR induced PSA-Luc transcription by 20-fold (Fig.
3B). These data demonstrate that one mechanism for CPIC
inhibition of AR-mediated transcription is by competing
with androgen binding to AR.
To evaluate the effect of CPIC on the interdomain AR N/C
interaction, we performedmammalian two-hybrid assays using
constructs containing the N- and C-terminal regions of AR.
Transfections were performed in HeLa cells using pCMV-AR-
(1–503) (the AR N-terminal region), pCMV-AR-(507–919)
(N-terminal deletion of AR), and PSA-Enh-Luc reporter plas-
mids in the absence and presence of 10 nM DHT. Bicalutamide
and other antagonists that bind to the ligand binding pocket of
AR disrupt this crucial interaction and alter receptor structure
and function (36, 37). CPIC was substantially more effective
than bicalutamide in inhibiting the androgen-induced AR N/C
interdomain interaction (Fig. 3C).
FIGURE 3. CPIC competes with androgens for binding to AR and reduces the AR N/C interaction. A, shown is a competitive radioligand binding assay.
Relative binding affinity of CPIC for AR was determined using 5 nM [3H]R1881 and a range of CPIC concentrations as described (31). Data are the average of
duplicate experiments. B, shown is the effect of DHT concentration on CPIC inhibition of AR-induced luciferase activity. HeLaA6 cells were seeded in 24-well
plates and maintained for 24 h in medium containing 0.1 nM DHT (circle) or 10 nM DHT (triangle) and the indicated concentrations of CPIC. Data represent the
average of triplicate experiments  S.E. C, HeLa cells were transfected with 100 ng of PSA-Enh-Luc reporter plasmid, 50 ng of pCMV-AR-(1–503), and 50 ng of
pCMV-AR-(507–919). Cells were incubated in the absence or presence of 10 nM DHT and the indicated concentrations of CPIC or Bic. Luciferase units of
DHT-treated wells were set at 100%. The luciferase activity is representative of two independent experiments.
FIGURE 4. Partial inhibition of ER activity at high concentrations of CPIC.
T47D-KBluc and T47D/(A1–2) cells were seeded in 24-well plates in medium
containing 5% CD-FBS. After the cells attached, treatment medium was
added with 5 nM 17-estradiol for ER in T47D-KBluc cells and 5 nM dexameth-
asone for GR in T47D/(A1–2) cells and the indicated concentrations of CPIC (or
DMSO vehicle). After 24 h cell lysates were analyzed for luciferase activity.
Data are the average of triplicate experiments  S.E.
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CPIC Is Relatively Specific Inhibitor of AR-mediated
Transactivation—The AR ligand binding domain shares 50%
sequence homology with the GR ligand-binding domain (38).
We, therefore, evaluated the effect of CPIC on transcription by
GR and ER in cell lines stably expressing reporter genes. Inhi-
bition of ER was evaluated in T47D-KBluc cells that express
endogenous ER and are stably transfected to express an
(ERE)3-luciferase reporter. Inhibition of GR was evaluated in
T47D/(A1–2) cells that stably express GR and a mouse mam-
mary tumor virus-luciferase reporter gene. Fig. 4 shows that
CPIC did not inhibit GR transcriptional activity and modestly
inhibited ER activity at 20 M CPIC. The results suggest that
CPIC is a relatively specific inhibitor of AR-mediated
transcription.
CPIC Inhibits AR-dependent Proliferation of Prostate Cancer
Cells—We evaluated the effect of CPIC on the proliferation of
AR positive prostate cancer cell lines. LAPC-4 cells contain
wild-type AR. LNCaP cells, the most widely used androgen-
sensitive cell line, contain high levels of the mutant AR-T877A,
and CWR-R1 cells contain mutant AR-H874Y, both of which
are highly inducible by androgens and other steroids (9, 39).
CPIC inhibited androgen-mediated AR-dependent growth of
all 3 cell lines, with an IC50 of 2 M in LNCaP cells (Fig. 5A),
0.3M in LAPC-4 cells (Fig. 5B), and5M in CWR-R1 cells
(Fig. 5C).
The specificity of CPIC inhibition of AR-mediated cell
growthwas tested usingAR-negative PC-3 andDU145 prostate
cancer cells and MDA-MB-231 breast cancer cells. CPIC had
little effect on the growth of PC-3 or MDA-MB-231 cells (Fig.
5D). However, at high concentrations, CPIC slowed but did not
arrest the proliferation of DU145 cells. Thus, functional con-
centrations of 5 M CPIC were relatively specific for inhibi-
tion of AR-mediated cell growth. We also evaluated several
small molecules structurally related to CPIC. These small mol-
ecules lacked the combined potency and specificity of CPIC.
One member of this structural family, PIC19.7 (2-methyl-1-(3-
(o-tolyloxy)propyl)-1H-indole-3-carbonitrile), exhibited an
excellent toxicity profile (supplemental Fig. S3) but had sub-
stantially lower potency than CPIC and inhibited ER-mediated
transactivation at high concentrations.
FIGURE 5. Effects of CPIC on prostate cancer cell growth. LNCaP cells (A), LAPC-4 cells (B), and CWR-R1 cells (C) were treated with the indicated concentrations
of CPIC in the presence or absence of 1 nM R1881. After 4 days of treatment for LNCaP and CWR-R1 cells and 8 days for slow-growing LAPC-4, cell proliferation
was measured using MTS. Cell growth in R1881DMSO was set to 100%. D, AR-negative PC-3, MDA-MB-231, and DU145 cells were inoculated at 2000 cells/well
in 96-well plates and treated with 100 l of medium containing the indicated concentrations of CPIC or DMSO (vehicle). Growth of the cells was evaluated after
3 days. DMSO wells were set to 100%. Data points represent the mean of 8 wells  S.E.
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CPIC Inhibits Anchorage-independent Growth of LAPC-4
Cells—Anchorage-independent growth is a hallmark of cancer
cells. Growth in soft agar is often used to evaluate anchorage
independence of human prostate cancer cells. We tested the
ability of CPIC to inhibit colony formation of wild-type AR
containing LAPC-4 cells grown in soft agar. LAPC-4 cells sup-
plemented with medium containing 1 nM R1881 formed large
colonies (0.5mm) after 4weeks (Fig. 6, R1881). The growth of
these cells was completely inhibited in the presence of 10 M
CPIC as well as 10 M Bic (Fig. 6). When colonies from all the
wells of each treatment condition were counted, the R1881-
treated plate contained 77 colonies/well mostly 0.5 mm in
diameter. In comparison, there were no colonies 0.5 mm in
diameter in the R1881 CPIC-treated wells and on average 2
small colonies/well less than 0.5 mm in diameter. A similar
effect was seen in the R1881 Bic-treated wells. The data indi-
cate that CPIC inhibits androgen stimulation of anchorage-de-
pendent (Fig. 5) and anchorage-independent (Fig. 6) growth of
prostate cancer cells.
CPIC Inhibits Expression of Endogenous AR-regulated Genes—
To evaluate the effect of CPIC on endogenous gene expression,
the levels of mRNAs for several well characterized androgen-
regulated genes were measured in LNCaP and LAPC-4 cells.
The PSA and TMPRSS2 genes are highly induced by androgens
acting throughAR. In LNCaP cells, 10MCPIC exhibited weak
agonist activity and blocked AR-mediated transcription of PSA
and TMPRSS2 mRNAs in a dose-dependent manner with IC50
values of 0.5 and 0.3 M, respectively (Fig. 7A). In contrast to
LNCaP cells, in LAPC-4 cells that express wild-type AR, CPIC
was a pure antagonist andwasmore effective than bicalutamide
in inhibiting induction of PSA and other genes (Fig. 7B and
supplemental Fig. S4B). TMPRSS2 mRNA was minimally
induced by androgen in LAPC-4 cells, and thus the effect of
CPIC could not be evaluated (data not shown). CPIC also inhib-
ited androgen-regulated expression of other genes including
kallikrein 2 and TMEPAI in LNCaP and LAPC-4 cells (supple-
mental Fig. S4).
The AR-T877A mutant in LNCaP cells is activated by adre-
nal androgens, estrogens, and progestins as well as many anti-
androgens (39), which may explain the weak agonist activity of
CPIC. Alternatively, higher levels of AR in LNCaP cells com-
pared with LAPC-4 cells (Fig. 1A) or cell type specificity might
be responsible for the weak agonist activity of CPIC. To test the
effect of the AR-T877A mutation, transient transfections were
performed in HeLa cells. For both wild-type AR and
AR-T877A, CPIC did not induce luciferase activity above the
no hormone control (supplemental Fig. S5). Because CPIC did
not exhibit weak agonist activity in HeLaA6 cells containing
high levels of wild-type AR (supplemental Fig. S1B) or in HeLa
cells transfected with AR-T877A (supplemental Fig. S5), it
seems likely that cell context contributes to the weak agonist
activity of CPIC in LNCaP cells.
CPIC Does Not Decrease AR Levels or Reduce Nuclear
Translocation—CPIC could inhibit AR-mediated gene expres-
sion through multiple mechanisms (40) that include (a)
increased AR degradation, (b) reduced nuclear localization of
liganded-AR, (c) inhibition of AR recruitment to response ele-
ments on DNA, and (d) altered coregulator recruitment.West-
ern blot analysis showed that CPIC had little or no effect on
intracellular levels of AR (Fig. 8A).
FIGURE 6. CPIC inhibits anchorage-independent growth of LAPC-4 prostate cancer cells in soft agar. 5000 LAPC-4 cells were plated into top agar. Cells
were treated with medium containing DMSO (vehicle), 1 nM R1881, 1 nM R1881  10 M CPIC, or 1 nM R1881  10 M Bic and replenished every 3– 4 days. After
28 days, colonies were counted and photographed at 5 magnification. Inset, the bar graph represents the average of the total number of colonies counted
in each well of the treatments. Photographs are representative of the entire well and of triplicate experiments.
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We used fluorescent polyclonal antibody to visualize intra-
cellular AR in LNCaP and LAPC-4 cells. ARwas predominantly
nuclear in the presence of 10 nM R1881. In LNCaP cells, when
10 M CPIC or Bic was present for either 4 or 24 h, AR was
predominantly localized in the nucleus (Fig. 8B and supple-
mental Fig. S6A). Staining DNA with DAPI showed nuclear
co-localization of CPIC-bound AR in LAPC-4 cells (supple-
mental Fig. S6B). These data suggest that CPIC promotes
nuclear localization of AR and might influence AR association
with DNA.
CPIC Inhibits AR Binding to Androgen-responsive Genes—
ChIP was used to evaluate the effect of CPIC on AR recruit-
ment to regulatory regions of androgen-responsive genes in
LNCaP and LAPC-4 cells. PSA and TMPRSS2 are two well
characterized androgen-regulated genes with defined AREs
in their promoter and enhancer regions (41, 42). In LNCaP
cells, R1881 increased AR recruitment to the PSA enhancer
and promoter regions (Fig. 9, A and B) and the TMPRSS2
enhancer (supplemental Fig. S7A). RNA polymerase II was
also recruited to theseAREs in the presence of androgen-bound
AR. Consistent with its weak agonist activity in LNCaP cells,
with 10MCPIC alone therewas a small increase in association
of AR with the PSA enhancer and promoter (Fig. 9, A and B).
Although there is diversity in the reported effects of bicalut-
amide onARbinding to the PSAenhancer in LNCaP cells (6, 43,
44), most reports suggest that bicalutamide interferes with
androgen action at the PSA promoter by altering AR interac-
FIGURE 7. CPIC inhibits expression of endogenous AR-regulated genes.
LNCaP (A) and LAPC-4 (B) cells were seeded in 6-well plates at 300,000 cells/
well in medium containing 5% CD-FBS for at least 3 days. Cells were treated
with or without 1 nM R1881 and the indicated concentrations of CPIC or Bic for
24 h before RNA extraction. mRNA was quantitated using quantitative RT-PCR
and normalized to -actin. Data represent the mean of three independent
experiments S.E.
FIGURE 8. CPIC does not decrease AR levels or alter nuclear localization of
AR. A, shown is a Western blot of AR levels in LNCaP cells treated with CPIC.
LNCaP cells were plated in medium containing 5% CD-FBS and maintained
for at least 3 days. Treatment medium with () or without () 10 nM DHT
containing DMSO (vehicle) or the indicated inhibitor was added to the cells.
After 24 h, cell lysates were prepared, and equal amounts of protein were
analyzed by Western blotting and tubulin used as a loading control. B, visu-
alization of intracellular AR in LNCaP cells is shown. LNCaP cells were incu-
bated with 10 nM R1881, 10 M Bic, or 10 M CPIC for 24 h, and intracellular AR
was visualized by fluorescent microscopy using AR polyclonal antibody
(Abcam, ab3510). Objective magnification, 40.
A Novel Inhibitor of AR Action in Prostate Cancer Cells
JULY 6, 2012 • VOLUME 287 • NUMBER 28 JOURNAL OF BIOLOGICAL CHEMISTRY 23375
tion with coregulators rather than inhibiting AR DNA binding
(34, 45, 46). We found that bicalutamide inhibited recruitment
of R1881-bound AR to the PSA enhancer to a greater extent
than the PSA-promoter (Fig. 9, A and B). CPIC strongly inhib-
ited recruitment of R1881-AR to the PSA-promoter, PSA-en-
hancer, and the TMPRSS2 enhancer (Fig. 9, A and B, and sup-
plemental Fig. S7A).
Because CPIC has no effect on AR levels or nuclear localiza-
tion (Fig. 8), the decrease in AR occupancy is likely an effect of
CPIC on AR binding to AREs and not a result of reduced levels
of nuclear AR. Consistent with its ability to reduce AR binding
to the promoter and enhancer regions of PSA and TMPRSS2,
CPIC also reduced recruitment of RNA polymerase II (Fig. 9, C
and D, and supplemental Fig. S7B). The results suggest that
CPIC inhibits AR binding to AREs.
In LNCaP cells, 10 M CPIC exhibits weak agonist activity at
the PSA gene (Figs. 7A and 9). To evaluate the effect of CPIC in
cells in which it acts as a pure antagonist, we performedChIP in
LAPC-4 cells. Because LAPC-4 cells contain lower levels of AR
relative to LNCaP cells, there are few instances of ChIP per-
formed using these cells. In LAPC-4 cells, 10 M CPIC in the
absence of R1881 did not increase AR occupancy at the PSA
enhancer or promoter (Fig. 10, A and B) or the kallikrein 2-en-
hancer (supplemental Fig. S7C). Bicalutamide had no effect on
R1881-AR recruitment at the PSA promoter, whereas CPIC
strongly inhibited R1881-AR recruitment to the PSA promoter
(Fig. 10B). CPIC was somewhat more effective than Bic in
reducing AR recruitment to the PSA enhancer (Fig. 10A). Con-
sistent with its inhibition of AR binding at the PSA regulatory
regions, CPIC also prevents recruitment of RNA polymerase II
(Fig. 10, C and D, and supplemental Fig. S7D).
To investigate the effect of CPIC on interaction of coactiva-
tors to AR, we used mammalian 2-hybrid assays. Because this
assay uses GAL4 DNA binding domain, we investigated the
effects of CPIC on coactivator recruitment independent of its
effects on AR binding to AREs in responsive genes. Previous
work showed that TIF2 (GRIP1/SRC2) interacts with the AR
ligand binding domain through its LXXLL motifs (1). In mam-
malian two-hybrid assays in HeLa cells, CPIC moderately
reduces the interaction between the AR ligand binding domain
and the TIF2 fragment required for interaction with AR (sup-
plemental Fig. S8). There was essentially no effect on TIF2
interaction at 5 M CPIC and 50% inhibition at 10 M CPIC.
We evaluated the relationship between the weak agonist
activity of CPIC in LNCaP cells that induced PSA and
TMPRSS2mRNAs and the extent to which CPIC enhances AR
occupancy at regulatory sites inPSA andTMPRSS2. CPIC alone
induced TMPRSS2mRNA to24% ofmaximum andAR bind-
ing to theTMPRSS2 enhancer to26%ofmaximum (Fig. 7 and
supplemental Fig. S7). There was also a correlation between the
ability of CPIC to inhibit R1881 induction of PSA and
TMPRSS2mRNAs and its ability to inhibit binding of AR to the
regulatory regions of these genes. These results suggest that
FIGURE 9. CPIC inhibits R1881-AR occupancy at AREs in LNCaP cells. Before ChIP, LNCaP cells were maintained for 3 days in medium containing 5% CD-FBS.
After 1 h of incubation with DMSO, 10 M CPIC, or 10 M Bic, the cells were treated with 1 nM R1881 or ethanol and incubated for 4 h. Protein complexes were
cross-linked, and AR (A, B) or RNA polymerase II (RNAPoIII; C, D) or control IgG antibody was used to pull down protein-bound chromatin fragments. Occupancy
at the PSA enhancer, PSA promoter, and a control ARE-free region (middle region) between the two sites was determined using quantitative RT-PCR. -Fold
enrichment over IgG control was plotted. Data represent the mean of three PCRs  S.E. and are representative of other experiments. Significance of the
differences between CPIC and the DMSO control was tested using Student’s t test. p  0.01 when compared with the respective controls. IP,
immunoprecipitate.
A Novel Inhibitor of AR Action in Prostate Cancer Cells
23376 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 287 • NUMBER 28 • JULY 6, 2012
CPIC acts by decreasing AR binding to AREs in androgen-re-
sponsive genes.
DISCUSSION
The importance of AR in the development and growth of
prostate cancer make AR an important therapeutic target. AR
has properties unique among the steroid receptor family that
influence androgen-dependent gene regulation. The AR inter-
domain interactions and a more limited role of coactivator
LXXLL motifs (1, 3) highlight significant differences between
AR and other steroid receptors. One way to probe the mecha-
nism of AR action is by identification and characterization of
novel small molecule inhibitors. The identification of a new
coactivator binding surface on AR using low potency small
molecule inhibitors, unrelated to CPIC, identified by screening
(47) supports the utility of using small molecules as probes of
AR actions. New small molecule inhibitors also have the poten-
tial to be therapeutically relevant.
Molecular mechanisms leading to the development of pros-
tate cancer resistance to antagonists are not fully understood.
In a limited number of cases, AR mutations such as AR-T877A
can confer resistance to anti-androgens that function as weak
agonists (39). To identify new small molecule AR inhibitors, we
developed and implemented a cell-based high-throughput
screen. Because LNCaP cells contain mutant AR-T877A and
LAPC-4 cells contain wild-type AR but have a doubling time of
3 days, these cell lines were unsuitable for a luciferase-based
screen. Although assays for androgen-stimulated proliferation
of LNCaP and LAPC-4 cells work well in a 96-well format, they
did not reach the requisite level of precision and reproducibility
needed for a high-throughput screen in 384-well plates. For
both the primary screen and preliminary analysis of hits, HeLa
cells stably expressing wild-type AR and a PSA-luciferase
reporter were used. The classical approach to cell-based
screening involves adding the test compounds to cells that are
previously plated. We found a simpler approach in which the
inhibitor and cells are added at the same time, produced equiv-
alent results, and could be readily automated. Consistent with
its properties in LNCaP cells stably transfected to express ele-
vated levels of wild-type AR (6), bicalutamide was an agonist in
the HeLaA6 cells that express high levels of AR compared with
minimal agonist activity inHeLa13 cells withmoderate levels of
AR similar to prostate cancer cells. In contrast to bicalutamide,
which did not inhibit the androgen-induced AR N/C interac-
tion at the submicromolar concentrations tested, CPIC
potently disrupted the androgen-dependent interdomain AR
N/C interaction.
Based on our assays, CPIC was selected for detailed evalua-
tion. An effective small molecule inhibitor of AR should exhibit
high potency and specificity.Our studies show thatCPIC inhib-
its AR transcriptional activity, with little or no effect on GR or
ER under the same conditions where other small molecules
robustly inhibited ER and GR (26, 48). CPIC effectively inhib-
FIGURE 10. CPIC inhibits R1881-AR occupancy at AREs in LAPC-4 cells. LAPC-4 cells were maintained for 3 days in medium containing 5% CD-FBS, and ChIP
was carried out as described in Fig. 9 and under “Experimental Procedures.” AR and RNA polymerase II occupancy at the PSA enhancer, PSA promoter, and a
control ARE-free region (middle region) between the two sites was determined using quantitative RT-PCR. -Fold enrichment over IgG control was plotted. Data
represent the mean of three PCRs  S.E. Significance of the differences between CPIC and the DMSO control was tested using Student’s t test and p  0.05 when
compared with the respective controls. For AR recruitment to the PSA promoter, R1881  10 M Bic was not significantly different from R1881  DMSO.
IP, immunoprecipitate.
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ited androgen-AR-dependent proliferation of LNCaP, LAPC-4,
and CWR-R1 prostate cancer cells. At relevant concentrations,
CPIC had little or no effect on the proliferation of several AR-
negative cell lines. Anchorage-independent colony formation is
a characteristic ofmany cancers, andCPIC nearly abolished the
AR-dependent proliferation of LAPC-4 prostate cancer cells in
soft agar. Our studies, therefore, suggest that CPIC is a potent
and selective inhibitor of AR action in prostate cancer cells.
Radioligand binding assays and gene expression studies
using stably transfected cell lines indicate that high levels of
CPIC compete with androgen binding. By far themost straight-
forward explanation of these data is that CPIC is a competitive
inhibitor of androgen binding to AR. However, our data do not
exclude the possibility that CPIC binds to AR outside of the
ligand binding pocket and induces an inactive AR conforma-
tion opposed to androgen binding. When very high concentra-
tions of androgens are present, AR is predominantly in the
active conformation, which suggests a competitor phenotype.
Although radioligand binding and cell-based assays show
that CPIC competes with androgen for binding to AR, the weak
agonist activity of CPIC in LNCaP cells did not result from the
AR-T877A mutation. Cell context and high AR-T877A are
likely responsible for the weak agonist activity of CPIC.
Interestingly, CPIC has a different site of action than two
experimental competitive inhibitors of AR, MDV3100 (6) and
ARN-509 (49). In part because MDV3100 required a relatively
high 100 mg/kg/day dose to elicit a maximum in vivo response,
ARN-509was produced that elicited amaximumresponse at 30
mg/kg/day. Amajor site of action of bothMDV3100 and ARN-
509 is inhibition of AR nuclear localization (6, 49). In contrast,
CPIC has no effect on nuclear localization and acts at the level
of AR binding to regulatory regions in responsive genes.
CPIC exhibited weak agonist activity in LNCaP cells and
modestly inducedPSAandTMPRSS2mRNAs in the absence of
androgen.However, 10MCPIC and 10Mbicalutamide alone
had similar minimal effects on the proliferation of LNCaP cells.
Tamoxifen, which competes with estrogens for binding to ER,
exhibits partial agonist activity in stimulating gene expression
in MCF-7 human breast cancer cells (50, 51) but is widely used
in breast cancer therapy. Because the weak agonist activity of
CPIC in LNCaP cells does not stimulate of LNCaP cell prolif-
eration, CPIC has therapeutic potential.
The inability of CPIC to influence AR levels or block agonist-
induced AR nuclear localization together with the results from
ChIP assays indicates that the inhibitory effects of CPIC occur
at the gene level. R1881 induced an 27-fold increase in AR
occupancy at the PSA enhancer, an 11-fold increase in occu-
pancy at the PSA promoter, and an 18-fold increase in occu-
pancy at the TMPRSS2 regulatory region. The extent to which
CPIC acts as a weak agonist in LNCaP cells and induced PSA
and TMPRSS2 mRNAs correlated with the extent to which
CPIC enhanced AR occupancy at regulatory sites in PSA and
TMPRSS2. These data suggest that CPIC-bound AR at the PSA
and TMPRSS2 genes is transcriptionally competent.
Consistent with the mRNA data, CPIC does not exhibit any
weak agonist activity in LAPC-4 cells. In these cells CPIC sig-
nificantly reduced androgen-induced AR recruitment and con-
sequently reduced RNA polymerase II recruitment to the PSA
promoter and enhancer regions. In contrast, bicalutamide in
the presence of androgen did not inhibit AR occupancy at the
PSA promoter in LNCaP cells (5) and has been reported to
recruit corepressors to the promoter region (34, 45). Our data
indicate that CPIC functions as an AR inhibitor by decreasing
the interaction of AR with regulatory regions of androgen-re-
sponsive genes.
AR and other steroid receptors exhibit a high level of confor-
mational flexibility. Small molecules such as CPIC and bicalu-
tamide may elicit different AR conformations. Our analysis
suggests that although CPIC is similar to bicalutamide in its
ability to inhibit androgen-induced transcription at the PSA
gene locus, they may evoke different conformational changes
when bound to AR and have different mechanisms of action.
CPIC was much more effective than bicalutamide in the
inhibition of R1881-AR binding to the PSA promoter. The
weak agonist activity of CPIC in LNCaP cells could be due to:
an AR conformation in which binding to AREs is reduced but
not eliminated; an altered coactivator population that stabi-
lizes weak binding of CPIC-AR to AREs; or the existence of
multiple CPIC-AR conformations, one of which binds DNA
and one of which is unable to bind DNA. With its unique
mode of action, CPIC is a new potential inhibitor of prostate
cancer growth.
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